• Molecular NameCevimeline
  • SynonymCevimeline hydrochloride; Cevimeline hydrochloride hemihydrate; Cevimeline hydrochloride hydrate
  • Weight199.318
  • Drugbank_IDDB00185
  • ACS_NO107233-08-9
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)2.07
  • pkaN/A
  • LogD (pH=7, predicted)-0.48
  • Solubility (experiment)Soluble
  • LogS (predicted, ACD/Labs)(ph=7)0.7
  • LogSw (predicted, AB/LogsW2.0)2.93
  • Sw (mg/ml) (predicted, ACD/Labs)24.21
  • No.of HBond Donors0
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds0
  • TPSA37.77
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA parasympathomimetic and muscarinic agonist
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding20.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmPrimarily hepatic, isozymes CYP2D6 and CYP3A4 are responsible for the metabolism of cevimeline. Approximately 44.5% of the drug is converted to cis and trans-sulfoxide, 22.3% to glucuronic acid conjugate, and 4% to N-oxide of cevimeline. Approximately 8% of the trans-sulfoxide metabolite is then converted into the corresponding glucuronic acid conjugate.
  • Half life5 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe following adverse events associated with muscarinic agonism were observed in the clinical trials of cevimeline in Sj?gren's syndrome patients: excessive sweating, nausea, rhinitis, diarrhea, excessive salivation, urinary frequency, asthenia, flushing, polyuria.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A